IP Library Granted Patent US 8,624,030
Granted Patent B2
US 8,624,030 · App. 13/196,929 · Granted Jan 7, 2014

N-demethylation of 6-keto morphinans

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,624,030
App. No.
13/196,929
Granted
Jan 7, 2014
Kind
B2
Abstract

The present invention provides processes for the demethylation of an N-methyl morphinan comprising a ketone functional group. In particular, the invention provides methods for the protection of the ketone functional group such that impurities are not generated during the demethylation of the N-methyl morphinan.

Claims (57)

1. A process for preparing a compound of Formula (III) from a compound of Formula (I), the process comprising:

a) contacting the compound of Formula (I) with an agent that forms a ketone protecting group such that a compound of Formula (II) is formed; and

b) contacting the compound of Formula (II) with an N-demethylating agent comprising LC(O)OZ and a proton acceptor to form the compound of Formula (III);

wherein:

R 1 and R 2 are independently chosen from hydrogen, halogen, hydroxy, amino, cyano, {—}OR 8 , hydrocarbyl, and substituted hydrocarbyl;

R 3 is chosen from hydrogen, hydrocarbyl, and substituted hydrocarbyl;

R 14 is chosen from hydrogen, halogen, hydroxy, {—}OR 8 , hydrocarbyl, and substituted hydrocarbyl;

R 8 and Z are independently chosen from hydrocarbyl and substituted hydrocarbyl;

L is halogen; and

Y is chosen from alkene acetal, dialkyl acetal, and enol ether, wherein each dashed line indicates an optional double bond.

2. The process of claim 1 , wherein:

R 1 , R 2 , and R 14 are independently chosen from hydrogen, halogen, hydroxy, alkyoxy, acyl, alkyl, alkenyl, aryl, substituted alkyl, substituted alkenyl, substituted aryl, alkoxycarbonyl, and aroxycarbonyl;

R 3 is chosen from hydrogen, alkyl, alkenyl, aryl, substituted alkyl, substituted alkenyl, substituted aryl, acyl, alkoxycarbonyl, aroxycarbonyl, acetal, ether, silyl ether, and alkylsulfonyl; and

Z is chosen from alkyl, alkenyl, alkylaryl, aralkyl, aryl, substituted alkyl, substituted alkenyl, substituted alkyiaryl, substituted aralkyl, and substituted aryl.

3. The process of claim 1 , wherein the compound of Formula (II) is chosen from:

(a) an alkene acetal of Formula (IIa) that is formed by contacting the compound of Formula (I) with an alkene diol and a proton donor, the compound of Formula (IIa) having the structure:

wherein:

R 1 and R 2 are independently chosen from hydrogen, halogen, hydroxy, amino, cyano, {—}OR 8 , hydrocarbyl, and substituted hydrocarbyl;

R 3 is chosen from hydrogen, hydrocarbyl, and substituted hydrocarbyl;

R 14 is chosen from hydrogen, halogen, hydroxy, {—}OR 8 , hydrocarbyl, and substituted hydrocarbyl; and

R 8 is chosen from hydrocarbyl and substituted hydrocarbyl;

(b) a dialkyl acetal of Formula (IIb) that is formed by contacting the compound of Formula (I) with at least one alcohol and a proton donor, the compound of Formula (IIb) having the structure:

wherein:

R 1 and R 2 are independently chosen from hydrogen, halogen, hydroxy, amino, cyano, {—}OR 8 , hydrocarbyl, and substituted hydrocarbyl;

R 3 is chosen from hydrogen, hydrocarbyl, and substituted hydrocarbyl;

R 14 is chosen from hydrogen, halogen, hydroxy, {—}OR 8 , hydrocarbyl, and substituted hydrocarbyl; and

R 5 , R 6 , and R 8 are independently chosen from hydrocarbyl and substituted hydrocarbyl; and

(c) an enol ether of Formula (IIc) that is formed either a) by contacting the compound of Formula (I) with an alcohol and a proton donor followed by distillation of the alcohol, or b) by contacting the compound of Formula (I) with a proton acceptor and a dialkyl sulfate, the compound of Formula (IIc) having the structure:

wherein:

R 1 and R 2 are independently chosen from hydrogen, halogen, hydroxy, amino, cyano, {—}OR 8 , hydrocarbyl, and substituted hydrocarbyl;

R 3 is chosen from hydrogen, hydrocarbyl, and substituted hydrocarbyl;

R 14 is chosen from hydrogen, halogen, hydroxy, {—}OR 8 , hydrocarbyl, and substituted hydrocarbyl; and

R 7 and R 8 are independently chosen from hydrocarbyl and substituted hydrocarbyl.

4. The process of claim 1 , wherein the reaction of step (a) is conducted in the presence of an aprotic solvent, a nonpolar solvent, or combinations thereof; the weight ratio of the solvent to the compound of Formula (I) is from about 0.5:1 to about 20:1; the reaction of step (a) is conducted at a temperature from about 0° C. to about 60° C.; the N-demethylating agent is chosen from alkyl haloformate, alkoxyalkyl haloformate, phenyl haloformate, benzyl haloformate, vinyl haloformate, and 2-chloroalkyl haloformate; the proton acceptor has a pKa greater than about 7; the molar ratio of the compound of Formula (II) to LC(O)OZ to the proton acceptor is from about 1:1:1 to about 1:3:6; the reaction of step (b) is conducted in the presence of a solvent chosen from acetonitrile, chlorobenzene, chloroform, 1,2-dichloroethane, ethyl acetate, n-propyl acetate, isopropyl acetate, tetrahydrofuran, toluene, and combinations thereof; the weight ratio of the solvent to the compound of Formula (II) is from about 0.5:1 to about 20:1; and the reaction of step (b) is conducted at a temperature from about 0° C. to about 120° C.

5. The process of claim 1 , wherein the compound of Formula (III) comprises less than about 0.05% by weight of an aldol dimer impurity.

6. The process of claim 1 , wherein the compound of Formula (III) has a yield of at least about 40% by weight.

7. The process of claim 1 , further comprising contacting the compound of Formula (III) with a nucleophile to form a compound of Formula (IV):

wherein:

R 1 and R 2 are independently chosen from hydrogen, halogen, hydroxy, amino, cyano, {—}OR 8 , hydrocarbyl, and substituted hydrocarbyl;

R 3 is chosen from hydrogen, hydrocarbyl, and substituted hydrocarbyl;

R 14 is chosen from hydrogen, halogen, hydroxy, {—}OR 8 ,hydrocarbyl, and substituted hydrocarbyl;

R 8 is hydrocarbyl or substituted hydrocarbyl; and

Y is chosen from cyclic alkene acetal, dialkenol acetal, and enol ether, wherein each dashed line indicates an optional double bond.

8. The process of claim 7 , wherein the nucleophile is chosen from an amide, an alkoxide, a hydride, and a hydroxide; and the molar ratio of the compound of Formula (III) to the nucleophile is from about 1:1 to about 1:8.

9. The process of claim 7 , further comprising contacting the compound of Formula (IV) with a proton donor to form a compound of Formula (V):

wherein:

R 1 and R 2 are independently chosen from hydrogen, halogen, hydroxy, amino, cyano, {—}OR 8 , hydrocarbyl, and substituted hydrocarbyl;

R 3 is chosen from hydrogen, hydrocarbyl, and substituted hydrocarbyl;

R 14 is chosen from hydrogen, halogen, hydroxy, {—}OR 8 ,hydrocarbyl, and substituted hydrocarbyl; and

R 8 is hydrocarbyl or substituted hydrocarbyl.

10. The process of claim 9 , wherein the proton donor has a pKa of less than about −2; and the molar ratio of the compound of Formula (IV) to the proton donor is about 1:2 to about 1:10.

11. The process of claim 1 , wherein the optical activity of the compounds of Formulas (I), (II), or (III) is chosen from (−) enantiomer, (+) enantiomer, and combinations thereof; and the configuration of C-5, C-13, C-14, and C-9, respectively, is chosen from RRRR, RRRS, RRSR, RSRR, SRRR, RRSS, RSSR, SSRR, SRRS, SRSR, RSRS, RSSS, SRSS, SSRS, SSSR, and SSSS, provided that C-15 and C-16 are both either on the alpha face or the beta face of the molecule.

12. The process of claim 3 , wherein the alkene diol is ethylene glycol;

the proton donor is methanesulfonic acid; the molar ratio of the compound of Formula (I) to ethylene glycol to methanesulfonic acid is about 1:4-30:3; and the reaction of step (a) is conducted at a temperature of less than about 40° C.

13. The process of claim 3 , wherein the proton acceptor is sodium hydride; the dialkyl sulfate is dimethyl sulfate; the molar ratio of the compound of Formula (I) to the proton acceptor to the dialkyl sulfate is about 1:1.5:1.4; and the reaction of step (a) is conducted at a temperature of less than about 40° C.

14. The process of 12 , wherein the N-demethylating agent is ethyl chloroformate or phenyl chloroformate; the proton acceptor is a carbonate or bicarbonate salt; the molar ratio of the compound of Formula (II) to the demethylating agent to the proton acceptor is from about 1:1.2:2-3; the reaction of step (b) is conducted at a temperature from about 40° C. to about 80° C.; the compound of Formula (Ill) comprises less than about 0.05% by weight of an aldol dimer impurity; and the optical activity of the compounds of Formulas (I), (II), or (III) is chosen from (−) enantiomer, (+) enantiomer, and combinations thereof; and the configuration of C-5, C-13, C-14, and C-9, respectively, is chosen from RRRR, RRRS, RRSR, RSRR, SRRR, RRSS, RSSR, SSRR, SRRS, SRSR, RSRS, RSSS, SRSS, SSRS, SSSR, and SSSS, provided that C-15 and C-16 are both either on the alpha face or the beta face of the molecule.

15. The process of 13 , wherein the N-demethylating agent is ethyl chloroformate or phenyl chloroformate; the proton acceptor is a carbonate or bicarbonate salt; the molar ratio of the compound of Formula (II) to the demethylating agent to the proton acceptor is from about 1:1.2:2-3; the reaction of step (b) is conducted at a temperature from about 40° C. to about 80° C.; the compound of Formula (III) comprises less than about 0.05% by weight of an aldol dimer impurity; and the optical activity of the compounds of Formulas (I), (II), or (III) is chosen from (−) enantiomer, (+) enantiomer, and combinations thereof; and the configuration of C-5, C-13, C-14, and C-9, respectively, is chosen from RRRR, RRRS, RRSR, RSRR, SRRR, RRSS, RSSR, SSRR, SRRS, SRSR, RSRS, RSSS, SRSS, SSRS, SSSR, and SSSS, provided that C-15 and C-16 are both either on the alpha face or the beta face of the molecule.

Assignments (14)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: SPECGX LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 31, 2025
From: SPECGX LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 072313/0063 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2017
From: MALLINCKRODT LLC
To: SPECGX LLC
Reel/Frame 044891/0376 →
SECURITY INTEREST Recorded Mar 19, 2014
From: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS INC.; MALLINCKRODT CARIBBEAN, INC.; MALLINCKRODT US POOL LLC; MALLINCKRODT INC.; LUDLOW CORPORATION; CNS THERAPEUTICS, INC.; ENTERPRISES HOLDINGS, INC.; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS, INC; MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC; MALLINCKRODT ENTERPRISES HOLDINGS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 032480/0001 →
CHANGE OF NAME Recorded Aug 4, 2011
From: MALLINCKRODT INC.
To: MALLINCKRODT LLC
Reel/Frame 026698/0475 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 4, 2011
From: WANG, PETER X.; JIANG, TAO; BERBERICH, DAVID W.; LIAO, SUBO
To: MALLINCKRODT INC.
Reel/Frame 026698/0304 →